10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: During the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of microvascular complications than did those receiving conventional dietary therapy. We conducted post-trial monitoring to determine whether this improved glucose control persisted and whether such therapy had a long-term effect on macrovascular outcomes. METHODS: Of 5102 patients with newly diagnosed type 2 diabetes, 4209 were randomly assigned to receive either conventional therapy (dietary restriction) or intensive therapy (either sulfonylurea or insulin or, in overweight patients, metformin) for glucose control. In post-trial monitoring, 3277 patients were asked to attend annual UKPDS clinics for 5 years, but no attempts were made to maintain their previously assigned therapies. Annual questionnaires were used to follow patients who were unable to attend the clinics, and all patients in years 6 to 10 were assessed through questionnaires. We examined seven prespecified aggregate clinical outcomes from the UKPDS on an intention-to-treat basis, according to previous randomization categories. RESULTS: Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea-insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). CONCLUSIONS: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. (UKPDS 80; Current Controlled Trials number, ISRCTN75451837.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential risks of intensive glycemic control may be obviated by incorporating agents that are not associated with hypoglycemia, especially in persons with frequent severe hypoglycemia, hypoglycemia unawareness, or a very long duration of DM, and particularly in the presence of established and advanced atherosclerosis, advanced age, and terminal illness.69,70,76–81”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [79]
In the citing paper
“it is worth noting the legacy effects of significant, early glucose lowering on macrovascular and microvascular complications observed in the UKPDS study [3,37].”
In the citing paper
“Although recidivism in glycemia is typically observed across all interventions in diabetes [4,5,6,29] including pharmaceutical interventions [3,37]”
In the citing paper
“Numerous studies have demonstrated the clinical benefits of early achievement of nearnormal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [81]
In the citing paper
“since optimal glycaemic control reduces the risk of both microvascular and macrovascular complications (36, 55).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [55]
31 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citationEuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Research works printed but not linked: 3
- 1959, Stat Bull Metrop Insur Co, 40, 1
- Nathan DM, 2005, N Engl J Med, 22, 2643
- 1993, N Engl J Med, 329, 997
Cited by
Items 501–600 of 1,169
Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes
Funk, S. D., Yurdagul, A., & Orr, A. W. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/569654 · Cited by 176
“Similarly, this group found a nonsignificant reduction in CVD events (16%) during the course of the trial [46] but a significant reduction in CVD events in a 10-year follow-up study [47].”
ResultTranslating the Diabetes Prevention Program Into Practice in the General Community
Amundson, H. A., Butcher, M. K., Gohdes, D., Hall, T. O., Harwell, T. S., Helgerson, S. D., Vanderwood, K. K., & Workgroup, M. C. D. A. D. P. P. (2009) · The Diabetes Educator · doi:10.1177/0145721709333269 · Cited by 174
Glucose variability: An emerging target for the treatment of diabetes mellitus
Frontoni, S., Di Bartolo, P., Avogaro, A., Bosi, E., Paolisso, G., & Ceriello, A. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.09.007 · Cited by 174
“In both T1DM and T2DM, prospective clinical studies have shown a strong correlation between the mean blood glucose values (evaluated by means of HbA1c) and diabetic complications [36-38].”
BackgroundRecent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy
Ola, M. S., Nawaz, M. I., Siddiquei, M. M., Al-Amro, S., & Abu El-Asrar, A. M. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.11.004 · Cited by 170
Lachin, J. M., & Nathan, D. M. (2021) · Diabetes Care · doi:10.2337/dc20-3097 · Cited by 163
“Reprinted with permission from the Journal of the American Medical Association (9).”
BackgroundShanbhogue, V. V., Hansen, S., Frost, M., Jørgensen, N. R., Hermann, A. P., Henriksen, J. E., & Brixen, K. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0860 · Cited by 171
Scheen, A. J., & Paquot, N. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.006 · Cited by 174
“89) [11].”
Sulfonylureas: A New Look at Old Therapy
Thulé, P. M., & Umpierrez, G. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0473-5 · Cited by 165
Lutgers, H. L., Gerrits, E. G., Graaff, R., Links, T. P., Sluiter, W. J., Gans, R. O., Bilo, H. J., & Smit, A. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1308-9 · Cited by 174
“This occurred despite the early loss of glycaemic and HbA1c differences, and adds further support to the above concept [22].”
Result6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s006 · Cited by 172
Greenfield, S., Billimek, J., Pellegrini, F., Franciosi, M., De Berardis, G., Nicolucci, A., & Kaplan, S. H. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-12-200912150-00005 · Cited by 170
Intensive glycemic control and cardiovascular disease: an update
Brown, A., Reynolds, L. R., & Bruemmer, D. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.35 · Cited by 173
“Interestingly, the results from long-term follow-up of patients in both the UKPD”
BackgroundRethink Organization to iMprove Education and Outcomes (ROMEO)
Trento, M., Gamba, S., Gentile, L., Grassi, G., Miselli, V., Morone, G., Passera, P., Tonutti, L., Tomalino, M., Bondonio, P., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2024 · Cited by 167
Dungan, J. S. (2011) · Yearbook of Obstetrics, Gynecology and Women's Health · doi:10.1016/j.yobg.2011.05.175 · Cited by 173
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 331
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 195
“Donnelly et al. analyzed data from A Diabetes Outcome Progression Trial (ADOPT) and UKPDS, and from real-world showed that the use of 1 g of metformin daily increased the risk of anemia by 2% per year [299].”
BackgroundInfluentialPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s61438 · Cited by 168
“randomized to receive intensive glucose therapy achieving a significant reduction in the risk of myocardial infarction and all-cause mortality.(68) On the other hand, two large CV outcome trials, ADVANCE (Action in Diabetes and Vascular disease: PreterAx and Diamicron – MR Controlled Evaluation)(69) and VADT (Veterans…”
BackgroundLazarus, B., Wu, A., Shin, J.-I., Sang, Y., Alexander, G. C., Secora, A., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 167
“Patientsusingmetforminmayhave lessweightgain, lower risk ofmyocardial infarction,andevenlowerlong-termmortalitythan those receiving other hypoglycemic therapies.(36,38,39)”
BackgroundSoluble forms of RAGE in internal medicine
Vazzana, N., Santilli, F., Cuccurullo, C., & Davì, G. (2009) · Internal and Emergency Medicine · doi:10.1007/s11739-009-0300-1 · Cited by 166
Growth Differentiation Factor 15 as a Novel Biomarker for Metformin
Gerstein, H. C., Pare, G., Hess, S., Ford, R. J., Sjaarda, J., Raman, K., McQueen, M., Lee, S., Haenel, H., & Steinberg, G. R. (2017) · Diabetes Care · doi:10.2337/dc16-1682 · Cited by 169
“(11); evidence thatmurine deletion of the GDF15 gene increases atherosclerosis (12), renal damage (13), and body weight (14); and evidence that the expression of GDF15 suppresses inflammation (12,13).”
BackgroundMicrovascular complications in diabetes: A growing concern for cardiologists
Avogaro, A., & Fadini, G. P. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.030 · Cited by 160
Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists
Fitridge, R., & Thompson, M. M. (2011) · Cited by 183
Li, Y., Tran, V. H., Duke, C. C., & Roufogalis, B. D. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/516870 · Cited by 161
“Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 516870, 10 pages doi:10.1155/2012/516870”
BackgroundInfluentialGenome-wide analysis reveals adaptation to high altitudes in Tibetan sheep
Wei, C., Wang, H., Liu, G., Zhao, F., Kijas, J. W., Ma, Y., Lu, J., Zhang, L., Cao, J., Wu, M., et al. (2016) · Scientific Reports · doi:10.1038/srep26770 · Cited by 162
Turning back time with emerging rejuvenation strategies
Mahmoudi, S., Xu, L., & Brunet, A. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0206-0 · Cited by 161
Contemporary Medical Management of Peripheral Artery Disease
Bonaca, M. P., Hamburg, N. M., & Creager, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318258 · Cited by 161
Pozzilli, P., Battelino, T., Danne, T., Hovorka, R., Jarosz‐Chobot, P., & Renard, E. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2653 · Cited by 160
Lind, M., Garcia-Rodriguez, L. A., Booth, G. L., Cea-Soriano, L., Shah, B. R., Ekeroth, G., & Lipscombe, L. L. (2013) · Diabetologia · doi:10.1007/s00125-013-3063-1 · Cited by 164
“higher in individuals with diabetes than in those without diabetes [6–13], with the majority of deaths being due to cardiovascular disease [3–6].”
BackgroundHypoglycemia, Diabetes, and Cardiovascular Disease
Snell-Bergeon, J. K., & Wadwa, R. P. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0031 · Cited by 161
“However, during the 10-year long-term follow-up, significant but modest reductions in CVD events were observed.(25) The results of these first two randomized clinical trials demonstrated that glucose lowering may modestly decrease macrovascular complications, but over a longer period of time than the much greater redu…”
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., Kahl, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 158
“Metformin Metformin reduces body weight, hepatic gluconeogenesis - by yet unclearmechanisms [106], and the risk ofmacrovascular complications, which is still controversially discussed due to lack of optimally designed clinical trials [107,108].”
Diabetic foot ulcer: Challenges and future
Li, Y., Rong, G.-C., & Wu, Q. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1014 · Cited by 188
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
“Reduction of atherosclerosis requires long-term treatment [53], hence longer trials are better suited to show a reduction in risk of myocardial infarction or other atherosclerotic complications of diabetes.”
BackgroundAdler, A. I., Coleman, R. L., Leal, J., Whiteley, W. N., Clarke, P., & Holman, R. R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00537-3 · Cited by 166
Self-citationRenin‐Angiotensin‐Aldosterone System in Diabetes and Hypertension
Hsueh, W. A., & Wyne, K. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00449.x · Cited by 160
Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives
Berezin, A. (2016) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2016.03.016 · Cited by 159
Marx, N., & McGuire, D. K. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw110 · Cited by 165
“Glucose-lowering and cardiovascular risk reduction in diabetes To date,(4) there is little proof that glycaemic control per se affects the risk for cardiovascular (CV) events.(5,6) Over the last decade, various CV outcome trials tested the effect of intensive glucose-lowering vs.”
BackgroundAdverse effects and safety of SGLT-2 inhibitors
Halimi, S., & Vergès, B. L. (2014) · Diabetes & Metabolism · doi:10.1016/s1262-3636(14)72693-x · Cited by 170
“In addition to lifestyle measures, which are always necessary, these drugs have demonstrated an ability to improve glycaemic control [2,3].”
BackgroundReactive oxygen species and endothelial function in diabetes
Fatehi-Hassanabad, Z., Chan, C. B., & Furman, B. L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.048 · Cited by 165
Yang, W., Liu, J., Shan, Z., Tian, H., Zhou, Z., Ji, Q., Weng, J., Jia, W., Lu, J., Liu, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70021-4 · Cited by 163
Luo, F., Das, A., Chen, J., Wu, P., Li, X., & Fang, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0860-y · Cited by 163
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, P. G., Davidson, J. A., Nicolau, J. C., Corbalan, R., Hirshberg, B., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1850 · Cited by 163
“Whether improvement in levels of either serum glucose and/or urinary albumin may translate into a cardioprotective benefit remains controversial (24,25).”
BackgroundCheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613489721 · Cited by 159
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases
Sandborn, W. J., Hanauer, S., Van Assche, G., Panés, J., Wilson, S., Petersson, J., & Panaccione, R. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2014.02.021 · Cited by 158
Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes
Ross, S. A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.012 · Cited by 172
Parati, G., Ochoa, J. E., Salvi, P., Lombardi, C., & Bilo, G. (2013) · Diabetes Care · doi:10.2337/dcs13-2043 · Cited by 158
Diabetes and its comorbidities—where East meets West
Kong, A. P. S., Xu, G., Brown, N., So, W.-Y., Ma, R. C. W., & Chan, J. C. N. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.102 · Cited by 159
Asghar, O., Alsunni, A. A., Khavandi, K., Khavandi, A., Withers, S., Greenstein, A. S., Heagerty, A. M., & Malik, R. A. (2009) · Clinical Science · doi:10.1042/cs20080500 · Cited by 187
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 206
“Long-term follow-up of the United Kingdom Prospective Diabetes Study (UKPDS) population supported a benefit of intensive therapy on macrovascular disease (49), but three other recent trials failed to demonstrate a significant difference in macrovascular disease outcomes between very intensive treatment strategies, whi…”
Usman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., Sreenivasan, J., & Golzar, Y. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318755531 · Cited by 160
Advani, A., Huang, Q., Thai, K., Advani, S. L., White, K., Kelly, D. J., Yuen, D. A., Connelly, K. A., Marsden, P. A., & Gilbert, R. E. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.01.044 · Cited by 167
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim-Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 155
Gaps and barriers in the control of blood glucose in people with type 2 diabetes
Blonde, L., Aschner, P., Bailey, C., Ji, L., Leiter, L. A., Matthaei, S., & Management, O. B. O. T. G. P. F. E. D. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116679775 · Cited by 146
“Publications were excluded from the review if they were (1) published before 2011 or (2) published in a language other than English.”
MethodInsulin Therapy for Type 2 Diabetes Mellitus
Wallia, A., & Molitch, M. E. (2014) · JAMA · doi:10.1001/jama.2014.5951 · Cited by 153
Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
Lomonaco, R., Sunny, N. E., Bril, F., & Cusi, K. (2013) · Drugs · doi:10.1007/s40265-012-0004-0 · Cited by 158
“Metformin still has clinical value in patients with NASH as it controls hyperglycaemia (common in these patients) and may reduce CVD in patients with T2DM [132].”
BackgroundGallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
Eddy, D., Schlessinger, L., Kahn, R., Peskin, B., & Schiebinger, R. (2009) · Diabetes Care · doi:10.2337/dc08-0854 · Cited by 156
Type 2 Diabetes Mellitus Management in Canada: Is It Improving?
Leiter, L. A., Berard, L., Bowering, C. K., CHENG, A. Y. Y., Dawson, K. G., Ékoé, J.-M., Fournier, C., Goldin, L., Harris, S. B., Lin, P., et al. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.055 · Cited by 173
Pathophysiology of type 2 diabetes and its treatment policy
加来, 浩. (2009) · 日本医師会雑誌 · Cited by 160
Primary prevention of ischaemic heart disease: populations, individuals, and health professionals
Gupta, R., & Wood, D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31893-8 · Cited by 172
Nishimura, E., Pridal, L., Glendorf, T., Hansen, B. F., Hubálek, F., Kjeldsen, T., Kristensen, N. R., Lützen, A., Lyby, K., Madsen, P., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002301 · Cited by 171
Bone disease in diabetes: another manifestation of microvascular disease?
Shanbhogue, V. V., Hansen, S., Frost, M., Brixen, K., & Hermann, A. P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30134-1 · Cited by 158
von Bibra, H., & St John Sutton, M. (2010) · Diabetologia · doi:10.1007/s00125-010-1682-3 · Cited by 158
Updates on the Management of Diabetes in Dialysis Patients
Rhee, C. M., Leung, A. M., Kovesdy, C. P., Lynch, K. E., Brent, G. A., & Kalantar‐Zadeh, K. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12198 · Cited by 169
Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients
Chen, S.-C., & Tseng, C.-H. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.88 · Cited by 152
“01) were noted during 10 years of post-trial follow-up, despite an early loss of glycemic differences [118].”
BackgroundSaisho, Y. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15050947 · Cited by 149
“The UK Prospective Diabetes Study (UKPDS) [1], Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) [2] and Kumamoto Study [3] have established the importance of glycemic control to prevent diabetic complications and based on this evidence, a glycated hemoglobin…”
BackgroundCardiovascular disease in chronic kidney disease
Marx-Schütt, K., Cherney, D. Z. I., Jankowski, J., Matsushita, K., Nardone, M., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf167 · Cited by 186
“33,34 Personalized HbA1c targets between 6.5% and 7.5% (48–58 mmol/mol) are recommended for people with diabetes and CKD; in principle, the best possible HbA1c level—even < 7.0% ( < 53 mmol/mol)—should be achieved, unless this goal is achieved by accepting hypoglycaemia.”
InfluentialO’Mahoney, L. L., Matu, J., Price, O. J., Birch, K. M., Ajjan, R. A., Farrar, D., Tapp, R., West, D. J., Deighton, K., & Campbell, M. D. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0740-x · Cited by 157
“While treatment for T2DM predominantly focuses on improving glycaemic control, lowering glucose only marginally reduces cardiovascular risk [2–6].”
Iglay, K., Cartier, S. E., Rosen, V. M., Zarotsky, V., Rajpathak, S. N., Radican, L., & Tunceli, K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1053048 · Cited by 157
“Meta-analysis The outcomes of interest for the meta-analysis were (1) mean adherence, defined as the average medication possession ratio (MPR); (2) proportion of adherent patients, defined as MPR 80%; (3) discontinuation, defined as the proportion of patients who discontinued medication use during the study period; an…”
BackgroundMethodInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
An update on advanced glycation endproducts and atherosclerosis
Del Turco, S., & Basta, G. (2012) · BioFactors · doi:10.1002/biof.1018 · Cited by 154
Madonna, R., & Caterina, R. D. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.03.005 · Cited by 180
“This delayed effect, apparent years after the conclusion of the randomized treatments, would demonstrate the cumulative effects of glucose toxicity on cardiovascular disease (Holman et al., 2008).”
BackgroundOptimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial
Wang, G., Liu, X., Ying, Z., Yang, G., Chen, Z., Liu, Z., Zhang, M., Yan, H., Lu, Y., Gao, Y., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02552-9 · Cited by 156
DURÁN, A., MARTÍN, P., RUNKLE, I., PÉREZ, N., ABAD, R., FERNÁNDEZ, M., DEL VALLE, L., SANZ, M. F., & CALLE‐PASCUAL, A. L. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00081.x · Cited by 156
Periodontitis and type II diabetes: a two-way relationship
Chee, B., Park, B., & Bartold, M. P. (2013) · International Journal of Evidence-Based Healthcare · doi:10.1111/1744-1609.12038 · Cited by 148
Epidemiological aspects of neoplasms in diabetes
Nicolucci, A. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0187-3 · Cited by 162
“While the benefits of a tight glycemic control, particularly in the early phases of the disease, are clearly documented [60], evidence of a possible increase in the risk of cancer associated with the use of some antidiabetic drug classes is contradictory and not substantiate by solid data.”
BackgroundThe Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
Avogaro, A., & Fadini, G. P. (2014) · Diabetes Care · doi:10.2337/dc14-0865 · Cited by 164
“up are likely needed to allow the effect of good glycemic control achieved with DPP4-I to translate into improved cardiovascular outcomes (3).”
BackgroundInfluentialThe genetics of diabetic complications
Ahlqvist, E., van Zuydam, N. R., Groop, L., & McCarthy, M. I. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.37 · Cited by 162
Bailey, C. J., Morales Villegas, E. C., Woo, V., Tang, W., Ptaszynska, A., & List, J. F. (2015) · Diabetic Medicine · doi:10.1111/dme.12624 · Cited by 154
Ratner, R., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 153
Mita, T., Katakami, N., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0781 · Cited by 152
“atherosclerosis in patients without history of CVD may increase the chance of significant reduction not only of microvascular disease but also CVD (16).”
BackgroundLipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes
TODAY Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2388 · Cited by 152
Deng, Y., Lu, L., Aponte, L., Angelidi, A. M., Novak, V., Karniadakis, G. E., & Mantzoros, C. S. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00480-x · Cited by 152
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Duckworth, W. C., Abraira, C., Moritz, T. E., Davis, S. N., Emanuele, N., Goldman, S., Hayward, R., Huang, G. D., Marks, J. B., Reaven, P. D., et al. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.10.003 · Cited by 152
Fujita, Y., & Inagaki, N. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12214 · Cited by 148
Song, S. H., & Hardisty, C. A. (2009) · QJM · doi:10.1093/qjmed/hcp121 · Cited by 147
“Recent evidence is accumulating to support the concept of cardiometabolic memory where intensive management of glycaemia and CVD risk factors during early stages of T2DM can lead to subsequent reduction in micro- and macrovascular complications much later in the course of disease.(11,12) Translating this concept into…”
BackgroundNeurodegeneration is an early event in diabetic retinopathy: therapeutic implications
Simó, R., Hernández, C., & on behalf of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)* (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-302005 · Cited by 150
for the Japan Diabetes Complications Study Group, Sone, H., Tanaka, S., Iimuro, S., Tanaka, S., Oida, K., Yamasaki, Y., Oikawa, S., Ishibashi, S., Katayama, S., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1622-2 · Cited by 151
“‘metabolic memory’ or ‘legacy effect’) [32, 33].”
Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes
Ross, S. A., Tildesley, H. D., & Ashkenas, J. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.621416 · Cited by 150
Cho, Y., Ann, S. H., Won, K., Park, G., Kim, Y., Yang, D. H., Kang, J., Lim, T., Kim, H., Choe, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42700-1 · Cited by 158
Rewiring of glucose metabolism defines trained immunity induced by oxidized low-density lipoprotein
Keating, S. T., Groh, L. A., Thiem, K., Bekkering, S., Li, Y., Matzaraki, V., van der Heijden, C. D. C. C., van Puffelen, J. H., Lachmandas, E., Jansen, T., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01915-w · Cited by 171
Yang, T., Feng, Q., Guo, F., Shao, M., Song, Y., Ren, G., Zhao, L., Qin, G., & Zhao, Y. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00824-9 · Cited by 179
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms
Tonna, S. J., El‐Osta, A., Cooper, M. E., & Tikellis, C. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.55 · Cited by 167
“the United Kingdom Prospective Diabetes Study (UKPDS)”
Gillett, M., Royle, P., Snaith, A., Scotland, G., Poobalan, A., Imamura, M., Black, C., Boroujerdi, M., Jick, S., Wyness, L., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16330 · Cited by 146
Caterson, I. D., Finer, N., Coutinho, W., Van Gaal, L. F., Maggioni, A. P., Torp‐Pedersen, C., Sharma, A. M., Legler, U. F., Shepherd, G. M., Rode, R. A., et al. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01554.x · Cited by 147
Gedebjerg, A., Almdal, T., Berencsi, K., Rungby, J., Nielsen, J. S., Witte, D. R., Friborg, S. G., Brandslund, I., Vaag, A. A., Beck‐Nielsen, H., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.09.010 · Cited by 171
Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., Wood, L., & Campbell, R. K. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.5.463 · Cited by 150
“In addition, the benefit of intensive glucose control seems to linger and have positive effects on cardiovascular outcomes and mortality well after clinical trial interventions have ended, as demonstrated in a 10-year follow-up study to the United Kingdom Prospective Diabetes Study (UKPDS).(9) Despite the clear need f…”
BackgroundGerstein, H. C., Miller, M. E., Ismail-Beigi, F., Largay, J., McDonald, C., Lochnan, H. A., & Booth, G. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60611-5 · Cited by 151
Metadata
- Authors
- Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W.
- Affiliations
- Churchill Hospital (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1577-1589
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2171294019
- Semantic Scholar
- 796f87021518c0bff851ff1ade5f780e3569e4ae
- Cited by
- 7,751
- References
- 55
- Citations by year
- 2026: 194 · 2025: 243 · 2024: 322 · 2023: 387 · 2022: 430 · 2021: 441 · 2020: 451 · 2019: 420 · 2018: 442 · 2017: 480 · 2016: 535 · 2015: 511 · 2014: 529 · 2013: 474 · 2012: 482
- FWCI
- 337.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Heart Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic control, metformin, sulfonylureas, insulin therapy, dietary therapy, microvascular complications, macrovascular outcomes, myocardial infarction, mortality, HbA1c, post-trial follow-up, UKPDS
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Myocardial Infarction, Risk, Sulfonylurea Compounds, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.